Image

The Hering-Breuer Reflex in Bilateral Lung Transplant Patients

The Hering-Breuer Reflex in Bilateral Lung Transplant Patients

Recruiting
18 years and older
All
Phase N/A

Powered by AI

Overview

The goal of this clinical trial (non-pharmacologic, single-center) is to determine whether the Hering-Breuer inflation reflex is preserved-and how it is modulated by end-expiratory pressure-in adult intensive-care patients who have undergone bilateral lung transplantation.

The study will enroll men and women ≥ 18 years admitted to the ICU during the early weaning phase and will include a comparison group of intubated ICU patients after major non-thoracic surgery.

The main questions it aims to answer are:

  • Is the Hering-Breuer reflex (measured as the ratio THBR/TSPONT) absent or attenuated in double-lung-transplant recipients?
  • Does changing the level of positive end-expiratory pressure (PEEP 8 vs 12 cmH₂O) influence the reflex?

Comparison group: Researchers will compare the transplant arm (post-bilateral lung transplantation) with the control arm (post-operative, non-thoracic surgery patients) to see whether loss or blunting of the reflex-and its response to PEEP-differs between the two cohorts.

Participants will:

  • Have a nasogastric catheter with embedded electrodes positioned to record the electrical activity of the diaphragm (EAdi).
  • Be ventilated in pressure-support mode at two preset PEEP levels (8 cmH₂O and 12 cmH₂O) during the weaning phase.
  • Receive one standardized high-volume insufflation at \~30 cmH₂O in each PEEP condition to elicit the reflex, while EAdi, airway pressures, inspiratory/expiratory times, and tidal volumes are recorded for 10 minutes per level.

Eligibility

Inclusion Criteria:

  • Age \>18 years;
  • Both sexes;
  • For group 1: patients admitted to the Intensive Care Unit after undergoing bilateral lung transplantation, during respiratory weaning;
  • For group 2: patients admitted to the Intensive Care Unit for support or monitoring after non-thoracic surgery, who will arrive intubated.

Exclusion Criteria:

For group 1, patients meeting at least one of the following criteria will be excluded:

  • Re-transplantation or single-lung transplantation;
  • Urgent lung transplantation;
  • Post-transplant respiratory system compliance \< 30 mL/cmH₂O;
  • Hemodynamic instability (defined as the presence of one or more of the following: plasma lactate \> 4 mmol/L, need for vasoactive support with norepinephrine and/or epinephrine at a dose \> 0.05 mcg/kg/min, systolic arterial pressure \< 80 mmHg);
  • Increased risk of bleeding related to the placement of a nasogastric tube due to coagulopathy or severe thrombocytopenia (INR \> 2 and platelets \< 70,000);
  • Pregnancy

For group 2, patients presenting with one or more of the following criteria will be excluded:

  • Postoperative respiratory system compliance \< 30 mL/cmH₂O;
  • Hemodynamic instability (defined as the presence of one or more of the following: plasma lactate \> 4 mmol/L, need for vasoactive support with norepinephrine and/or epinephrine at a dose \> 0.05 mcg/kg/min, systolic arterial pressure \< 80 mmHg);
  • Contraindications to nasogastric tube placement (gastroesophageal surgery within the last 3 months, gastroesophageal bleeding in the previous 30 days, esophageal varices, facial trauma);
  • Increased risk of bleeding related to the placement of a nasogastric tube due to coagulopathy or severe thrombocytopenia (INR \> 2 and platelets \< 70,000);
  • History of lung transplantation or major thoracic surgery;
  • Pregnancy.

Study details
    Hering-Breuer Reflex

NCT07280611

Policlinico Hospital

31 January 2026

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.